Lyra therapeutics to participate in upcoming investor conferences

Watertown, mass., nov. 07, 2023 (globe newswire) -- lyra therapeutics, inc. (nasdaq: lyra), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (crs), today announced that maria palasis, ph.d., president and chief executive officer, will participate in the following investor conferences in november:
LYRA Ratings Summary
LYRA Quant Ranking